Compare GSK plc (GSK) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares Core High Dividend ETF — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while iShares Core High Dividend ETF trades at $28.27. The key difference: GSK plc pays a 3.49% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | HDV | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $28.09 |
52-Week Low | $36.20 | $23.64 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
HDV, the iShares Core High Dividend ETF, trades at $28.20, up 2.03% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent corporate actions include a 1:5 stock split in April 2026 and upcoming dividend payments. The ETF focuses on large-cap value stocks with a defensive tilt, emphasizing high-quality, dividend-paying companies. News coverage highlights its competitive expense ratio and comparisons with peers like SCHD and VYM.
The outlook for HDV is supported by its defensive sector allocation and income focus, appealing in uncertain markets. Risks include concentration in energy and healthcare, which may introduce volatility. Analyst sentiment is mixed, weighing yield against diversification. The ETF suits investors seeking steady dividends with moderate growth, but sector-specific risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
